China Jo-Jo Drugstores 10-Q 14 Nov 13 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2013	Nov. 13, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CHINA JO-JO DRUGSTORES, INC.	'
Entity Central Index Key	'0001413263	'
Trading Symbol	'cjjd	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	13,959,002
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Sep. 30, 2013	Mar. 31, 2013
CURRENT ASSETS	'	'
Cash	$6,296,715	$4,524,094
Trade accounts receivable, net	12,691,630	12,978,808
Inventories	12,167,632	8,586,999
Other receivables, net	425,902	157,849
Advances to suppliers, net	11,070,649	15,523,034
Restricted cash	1,964,313	2,162,837
Other current assets	2,140,802	1,221,499
Total current assets	46,757,643	45,155,120
PROPERTY AND EQUIPMENT, net	12,712,963	13,288,652
OTHER ASSETS	'	'
Long term deposits	4,184,317	2,760,665
Other noncurrent assets	5,460,500	5,431,326
Intangible assets, net	1,149,981	1,202,258
Total other assets	10,794,798	9,394,249
Total assets	70,265,404	67,838,021
CURRENT LIABILITIES	'	'
Short-term loan payable	163,000	'
Accounts payable, trade	19,455,279	13,780,211
Notes payable	6,547,710	7,186,453
Other payables	1,429,961	1,327,454
Other payables - related parties	2,104,735	1,224,417
Customer deposits	1,989,967	4,828,293
Taxes payable	379,981	371,633
Accrued liabilities	242,843	956,342
Total current liabilities	32,313,476	29,674,803
Purchase option derivative liability	60,043	15,609
Total liabilities	32,373,519	29,690,412
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of September 30, 2013 and March 31, 2013	'	'
Common stock; $0.001 par value; 250,000,000 shares authorized; 13,609,002 shares issued and outstanding as of September 30, 2013 and March 31, 2013	13,609	13,609
Additional paid-in capital	16,668,548	16,609,747
Statutory reserves	1,309,109	1,309,109
Retained earnings	15,761,791	17,095,369
Accumulated other comprehensive income	4,141,259	3,121,654
Total stockholders' equity	37,894,316	38,149,488
Noncontrolling interests	-2,431	-1,879
Total equity	37,891,885	38,147,609
Total liabilities and stockholders' equity	$70,265,404	$67,838,021

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthenticals) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	13,609,002	13,609,002
Common stock, shares outstanding	13,609,002	13,609,002

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
REVENUES, NET	$16,855,421	$26,665,114	$32,191,940	$59,512,445
COST OF GOODS SOLD	13,907,018	23,242,917	25,642,368	50,945,471
GROSS PROFIT	2,948,403	3,422,197	6,549,572	8,566,974
SELLING EXPENSES	2,979,131	2,102,621	4,659,973	3,960,845
GENERAL AND ADMINISTRATIVE EXPENSES	491,981	1,310,313	3,132,799	4,156,892
TOTAL OPERATING EXPENSES	3,471,112	3,412,934	7,792,772	8,117,737
(LOSS) INCOME FROM OPERATIONS	-522,709	9,263	-1,243,200	449,237
OTHER INCOME (LOSS), NET	37,021	-90,332	-3,392	8,367
GOODWILL IMPAIRMENT LOSS	'	-1,473,606	'	-1,473,606
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES	-21,049	25,905	-8,384	25,747
LOSS BEFORE INCOME TAXES	-506,737	-1,528,770	-1,254,976	-990,255
PROVISION FOR INCOME TAXES	39,589	10	79,109	3,892
NET LOSS	-546,326	-1,528,780	-1,334,085	-994,147
ADD: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST	264	331	507	585
NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.	-546,062	-1,528,449	-1,333,578	-993,562
OTHER COMPREHENSIVE INCOME	'	'	'	'
Foreign currency translation adjustments	259,814	52,538	1,019,605	107,547
COMPREHENSIVE LOSS	($286,248)	($1,475,911)	($313,973)	($886,015)
WEIGHTED AVERAGE NUMBER OF SHARES:	'	'	'	'
Basic (in shares)	13,609,003	13,588,569	13,609,003	13,575,550
Diluted (in shares)	13,609,003	13,588,569	13,609,003	13,575,550
LOSSES PER SHARES:	'	'	'	'
Basic (in dollars per share)	($0.04)	($0.11)	($0.10)	($0.07)
Diluted (in dollars per share)	($0.04)	($0.11)	($0.10)	($0.07)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($1,334,085)	($994,147)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	1,140,586	1,295,175
Stock compensation	58,801	97,236
Bad debt write-off and provision	-747,930	834,772
Goodwill Impairment	'	1,473,606
Change in fair value of purchase option derivative liability	8,384	-25,747
Change in operating assets:	'	'
Accounts receivable, trade	972,975	-11,009,813
Notes receivable	'	-928,801
Inventories	-3,361,143	-1,887,064
Other receivables	-262,493	-761,810
Advances to suppliers	5,117,601	-2,040,116
Other current assets	-849,209	-779,191
Long term deposit	'	421,871
Other noncurrent assets	92,785	251,938
Change in operating liabilities:	'	'
Accounts payable, trade	5,323,371	9,916,586
Other payables and accrued liabilities	-654,911	715,342
Customer deposits	-2,925,130	1,657,754
Taxes payable	-45	-242,908
Net cash provided by (used in) operating activities	2,579,557	-2,005,317
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchase of equipment	-54,413	-234,151
Increase in long-term deposits for land use right	-1,351,030	'
Additions to leasehold improvements	-26,619	-253,163
Payments on construction-in-progress	-111,524	'
Net cash used in investing activities	-1,543,586	-487,314
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from short-term bank loan	161,770	'
Change in restricted cash	245,504	90,544
Change in notes payable	-795,002	2,328,686
Change in other payables-related parties	879,958	-295,954
Net cash provided by financing activities	492,230	2,123,276
EFFECT OF EXCHANGE RATE ON CASH	244,420	44,100
INCREASE (DECREASE) IN CASH	1,772,621	-325,255
CASH, beginning of period	4,524,094	3,833,216
CASH, end of period	6,296,715	3,507,961
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:	'	'
Cash paid for income taxes	12,797	'
Transfer from construction-in-progress to leasehold improvement	'	$2,703,428

DESCRIPTION_OF_BUSINESS_AND_OR

DESCRIPTION OF BUSINESS AND ORGANIZATION	6 Months Ended
	Sep. 30, 2013
Description Of Business and Organization [Abstract]	'
DESCRIPTION OF BUSINESS AND ORGANIZATION	'
	Note 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION
	China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), was incorporated in Nevada on December 19, 2006, originally under the name “Kerrisdale Mining Corporation.” On September 24, 2009, the Company changed its name to “China Jo-Jo Drugstores, Inc.” in connection with a share exchange transaction as described below.
	On September 17, 2009, the Company completed a share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”), whereby 7,900,000 shares of common stock were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization and, as a result, the consolidated financial statements of the Company (the legal acquirer) is, in substance, those of Renovation (the accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment Management Co., Ltd. (“Jiuxin Management”), Zhejiang Shouantang Medical Technology Co., Ltd. (“Shouantang Technology”) and Hangzhou Jiutong Medical Technology Co., Ltd (“Jiutong Medical”), its wholly-owned subsidiaries.
	The Company is a retail and wholesale distributor of pharmaceutical and other healthcare products in the People’s Republic of China (“China” or the “PRC”). The Company’s retail business is comprised primarily of pharmacies, a majority of which are operated by Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (“Jiuzhou Pharmacy”), a company that the Company controls through contractual arrangements. Shanghai Lydia Grand Pharmacy Co., Ltd. (“Shanghai Lydia”), a wholly-owned subsidiary of Jiuzhou Pharmacy, operates two store locations in Shanghai. On July 29, 2011, Shanghai Lydia obtained control of Shanghai Bieyanghong Zhongxing Grand Pharmacy Co. Ltd., which also operates one pharmacy in Shanghai, and which subsequently changed its name to Shanghai Lydia Zhongxing Grand Pharmacy Co., Ltd. (“Shanghai Zhongxing”). Shanghai Lydia has two additional subsidiaries, namely, Shanghai Lydia Trading Co., Ltd. (“Lydia Trading”), which operates one pharmacy in Shanghai, and Shanghai Lydia Zhenguang Grand Pharmacy Co., Ltd. (“Shanghai Zhenguang”), which operates another pharmacy in Shanghai. One drugstore previously operated by Hangzhou Quannuo Grand Pharmacy Co., Ltd. (“Hangzhou Quannuo”) closed in May 2012. Hangzhou Quannuo is the wholly-owned subsidiary of Zhejiang Quannuo Internet Technology Co., Ltd. (“Quannuo Technology”), which is wholly-owned by Shouantang Technology. At September 30, 2013, Hangzhou Quannuo had not been dissolved but had no operation.
	The Company’s retail business also includes four medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (“Jiuzhou Clinic”) and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (“Jiuzhou Service”), both of which are also controlled by the Company through contractual arrangements.
	The Company’s wholesale business is primarily conducted through Zhejiang Jiuxin Medicine Co., Ltd. (“Jiuxin Medicine”), which is licensed to distribute prescription and non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011.
	The Company’s herb farming business is conducted by Hangzhou Qianhong Agriculture Development Co., Ltd. (“Qianhong Agriculture”), a wholly-owned subsidiary of Jiuxin Management, which operates a cultivation project of herbal plants used for traditional Chinese medicine (“TCM”).
	The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities:
	Entity Name		Background	Ownership
	Renovation HK		● Incorporated in Hong Kong SAR on September 2, 2008	100%
	Jiuxin Management		● Established in the PRC on October 14, 2008	100%
			● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law
			● Registered capital of $4.5 million fully paid
	Shouantang Technology		● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million	100%
			● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid
			● Deemed a WFOE under PRC law
			● Invests and finances the working capital of Quannuo Technology
	Qianhong Agriculture		● Established in the PRC on August 10, 2010 by Jiuxin Management	100%
			● Registered capital of RMB 10 million fully paid
			● Carries out herb farming business
	Quannuo Technology		● Established in the PRC on July 7, 2009	100%
			● Registered capital of RMB 10 million fully paid
			● Acquired by Shouantang Technology in November 2010
			● Operates the Company’s online pharmacy website and provide software and technical support
	Hangzhou Quannuo		● Established in the PRC on July 8, 2010 by Quannuo Technology	100%
			● Registered capital of RMB 800,000 fully paid
			● Currently has no operation
	Jiuzhou Pharmacy (1)		● Established in the PRC on September 9, 2003	VIE by contractual  arrangements (2)
			● Registered capital of RMB 5 million fully paid
			● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou
	Jiuzhou Clinic (1)		● Established in the PRC as a general partnership on October 10, 2003	VIE by contractual arrangements (2)
			● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores
	Jiuzhou Service (1)		● Established in the PRC on November 2, 2005	VIE by contractual  arrangements (2)
			● Registered capital of RMB 500,000 fully paid
			● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores
	Shanghai Lydia		● Established in the PRC on January 31, 2011 by Jiuzhou Pharmacy	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)
			● Registered capital of RMB 1 million fully paid
			● Operates the “Lydia Grand Pharmacy” and “Chaling Grand Pharmacy”  stores in Shanghai
	Jiuxin Medicine		● Established in PRC on December 31, 2003	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)
			● Acquired by Jiuzhou Pharmacy in August 2011
			● Registered capital of RMB 10 million fully paid
			● Carries out pharmaceutical distribution services
	Shanghai Zhongxing		● Established in PRC on June 19, 2006	VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia (2)
			● Registered capital of RMB 1 million fully paid
			● 99% acquired by Shanghai Lydia in July 2011
			● Operates the “Zhongxing Grand Pharmacy” store in Shanghai
	Lydia Trading		● Established in the PRC on June 20, 2012 with registered capital of RMB 1 million fully paid	VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia (2)
			● Operates one “Weifang Grand Pharmacy” store in Shanghai
	Shanghai Zhenguang		● Established in the PRC on October 31, 2012 with registered capital of RMB 500,000 fully paid	VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia (2)
			● Operates the “Zhenguang Grand Pharmacy” store in Shanghai
	Jiutong Medical		● Established in the PRC on December 20, 2011 by Renovation with registered capital of $5 million	100%
			● $2.6 million of registered capital paid, with the remaining $2.4 million due by December 20, 2013
			● Currently has no operation
	-1	Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of their three cofounders (the “Owners”) since their respective establishment dates, pursuant to agreements amongst the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies in accordance with generally accepted accounting standards. Operationally, the Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Shanghai Lydia, Shanghai Zhongxing, Lydia Trading, Shanghai Zhenguang and Jiuxin Medicine are also deemed under the common control of the Owners as they are each a subsidiary of Jiuzhou Pharmacy.
	-2	To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as the two subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries and entity under the control of Jiuzhou Pharmacy (Shanghai Lydia, Jiuxin Medicine, Shanghai Zhongxing, Lydia Trading and Shanghai Zhenguang), are consolidated into the financial statements of the Company.

LIQUIDITY

LIQUIDITY	6 Months Ended
	Sep. 30, 2013
Liquidity [Abstract]	'
LIQUIDITY	'
	Note 2 – LIQUIDITY
	As reflected in the Company’s condensed consolidated financial statements, the Company had net loss for the three and six months ended September 30, 2013.  In assessing its liquidity, management monitors and analyzes the Company’s cash on-hand, its ability to renew bank facilities, and its operating and capital expenditure commitments.  Its principal liquidity needs are to meet its working capital requirements, operating expenses and capital expenditure obligations, although the Company’s accounts payable did increase by approximately $5.7 million for additional inventory purchases of membership rewards in connection with Jiuzhou Pharmacy’s 10-year anniversary, and in preparation for the upcoming shopping season.
	The Company’s principal sources of liquidity consist of existing cash on hand, bank facilities from local banks as well as personal loans from its principal shareholders if necessary.  The Company has a loan agreement to borrow up to $5.3 million from a local bank.  Any borrowing therefrom is secured by the Company’s assets pursuant to a collateral agreement, as well as the personal guarantees of some of its principal shareholders.  As of September 30, 2013, approximately $3.9 million remained available for future borrowing from such bank.  In addition, a principal shareholder has agreed to provide necessary financial support to meet the Company’s financial obligations in the event that it requires additional liquidity.
	On the operating side, the Company plans to fund current operations by adjusting its wholesale business operations to focus on profitability rather than sales volume, expanding online sales and focusing on strengthening and expanding its core business model of integrating pharmacies with medical clinic services, which has proven to be a key profit driver.  The Company also plans to control its general and administrative expenses by identifying and eliminating unnecessary administrative costs such as overcapacity in administrative personnel and related office expenses.
	Management believes that the foregoing measures collectively will provide sufficient liquidity for the Company to meet its future liquidity and capital obligations.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation and consolidation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“US GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. These condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2013 filed with the SEC on July 1, 2013. Operating results for the three and six months ended September 30, 2013 may not be necessarily indicative of the results that may be expected for the full year.
	The condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and VIEs.  All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.
	Consolidation of variable interest entities
	In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes.
	The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns.
	Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements.
	Control and common control is defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized the Voting Rights Proxy Agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company.
	Risks and Uncertainties
	The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.
	The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its vendors or landlords.
	Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC.  The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns.  As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs.
	Use of estimates
	The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable and related allowance for doubtful accounts, useful lives of property and equipment, and fair value of purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.
	Intangibles
	Intangible assets, whether acquired individually or as part of a group of assets, are initially recorded at their fair value.  The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values.
	The estimated useful lives of the Company’s intangible assets are as follows:
		Estimated Useful Life
	Licenses and permits	Indefinite
	Software	3 years
	The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired.
	There was no intangible impairment during the three and six months ended September 30, 2013.
	Revenue recognition
	Revenue from sales of prescription medicine at the drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription.
	Revenue from sales of other merchandise at the drugstores is recognized at the point of sale, which is when the customer pays for and receives the merchandise.
	Revenue from medical services is recognized after the service has been rendered to the customer.
	Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal.
	The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.
	Restricted cash
	The Company’s restricted cash consists of cash in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.
	Accounts receivable
	Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, and (3) amounts due from non-retail customers for sales of merchandise.
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate.
	In its retail business, accounts receivable mainly consist of reimbursements due from government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which is determined to be uncollectable after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trend.
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined using the first in first out (FIFO) method. Market is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at its purchase price, which includes direct cost such as seed selection, fertilizer, labor costs and contract fee that are spent in growing herbs on the leased farmland, and indirect cost which includes amortization of farmland development cost. All the costs are accumulated until the time of harvest and then allocated to harvested herbs upon sales. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified.  Historically, these amounts have not been material to the consolidated financial statements.
	Property and equipment
	Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment:
		Estimated Useful Life
	Leasehold improvements	3-10 years
	Motor vehicles	5 years
	Office equipment & furniture	3-5 years
	Buildings	10 years
	Maintenance, repairs and minor renewals are charged to expense as incurred. Major additions and betterment to property and equipment are capitalized.
	Impairment of long lived assets
	The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There was no impairment of these assets as of September 30, 2013.
	Notes payable
	During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months.
	Income taxes
	The Company records income taxes pursuant to the accounting standards for income taxes. These standards require the recognition of deferred income tax liabilities and assets for the expected future tax consequences of temporary differences between income tax basis and financial reporting basis of assets and liabilities. Provision for income taxes consists of taxes currently due and the net change in deferred taxes.  A valuation allowance is recognized if it is more likely than not that some portion, or all of, a deferred tax asset will not be realized.
	Stock based compensation
	The Company follows the provisions of ASC 718, “Compensation — Stock Compensation,” which establishes the accounting for non-employee and employee stock-based awards. Under the provisions of ASC 718, the fair value of the stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award.
	Advertising and promotion costs
	Advertising and promotion costs are expensed as incurred and amounted to $18,632 and $36,886 for three months ended September 30, 2013 and 2012, respectively, and $56,533 and $75,139 for the six months ended September 30, 2013 and 2012, respectively. Such costs consist primarily of print and television advertisements.
	Foreign currency translation
	The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC.
	In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income.
	The balance sheet amounts, with the exception of equity, at September 30, 2013 and March 31, 2013 were translated at 1 RMB to $0.1630 USD and at 1 RMB to $0.1594 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2013 and 2012 were at 1 RMB to $0.1618 USD and at 1 RMB to $0.1580 USD, respectively.
	Concentrations and credit risk
	Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Balances at financial institutions and state-owned banks within the PRC are not covered by insurance. As of September 30, 2013 and March 31, 2013, the Company had deposits totaling $7,912,547 and $6,230,011 that were not covered by insurance, respectively. To date, the Company has not experienced any losses in such accounts.
	For the three months ended September 30, 2013, no vendor accounted for more than 10% of the Company’s total purchases and one vendor accounted for 20% of total advances to suppliers. For the three months ended September 30, 2012, one vendor accounted for approximately 12% of the Company’s total purchases and another vendor accounted for 22% of total advances to suppliers.
	For the six months ended September 30, 2013, one vendor accounted for 10% of the Company’s total purchases and another vendor accounted for 20% of total advances to suppliers. For the six months ended September 30, 2012, one vendor accounted for approximately 13% of the Company’s total purchases and another vendor accounted for 22% of total advances to suppliers.
For the three months ended September 30, 2013, no customer accounted for more than 10% of the Company’s total sales and one customer accounted for 12% of total accounts receivable. For the three months ended September 30, 2012, one customer accounted for approximately 16% of the Company’s total sales and another customer accounted for 15% of total accounts receivable.
For the six months ended September 30, 2013, no customer accounted for more than 10% of the Company’s total sales, and one customer accounted for 12% of total accounts receivable. For the six months ended September 30, 2012, one customer accounted for approximately 14% of the Company’s total sales and another customer accounted for 15% of total accounts receivable.
Noncontrolling interest
As of September 30, 2013, 1% of the equity interests of Shanghai Zhongxing was owned by Shanghai Bieyanghong Grand Pharmacy Co., Ltd. and not under the Company's control.

TRADE_ACCOUNTS_RECEIVABLE

TRADE ACCOUNTS RECEIVABLE	6 Months Ended
	Sep. 30, 2013
Accounts Receivable, Net [Abstract]	'
TRADE ACCOUNTS RECEIVABLE	'
	NOTE 4 – TRADE ACCOUNTS RECEIVABLE
	Trade accounts receivable consisted of the following:
		September 30,			March 31,
		2013			2013
	Accounts receivable	$	17,179,460		$	18,007,051
	Less: allowance for doubtful accounts		(4,487,830	)		(5,028,243	)
	Trade accounts receivable, net	$	12,691,630		$	12,978,808
	For the three months ended September 30, 2013 and 2012, $96,250 and $155,296 in accounts receivable were directly written off, respectively, none of which were written off against previous allowance for doubtful accounts.
	For the six months ended September 30, 2013 and 2012, $347,395 and $310,461 in accounts receivable were directly written off, respectively, $364,608 and $0 of which were written off against previous allowance for doubtful accounts, respectively.

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	6 Months Ended
	Sep. 30, 2013
Other Current Assets [Abstract]	'
OTHER CURRENT ASSETS	'
	Note 5 – OTHER CURRENT ASSETS
	Other current assets consisted of the following:
			September 30,		March 31,
			2013		2013
	Prepaid rental expenses		$	1,730,847	$	647,489
	Lease rights transfer fees (1)			72,916		247,789
	Prepaids and other current assets			337,039		326,221
	Total		$	2,140,802	$	1,221,499
	-1	Lease rights transfer fees are paid by the Company to secure store rentals in coveted areas. These additional costs of acquiring the right to lease new store locations are capitalized and amortized over the period of the initial lease term.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	6 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	Note 6 – PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following:
		September 30,			March 31,
		2013			2013
	Building	$	1,144,326		$	1,119,053
	Leasehold improvements		14,298,631			13,956,605
	Office equipment and furniture		5,438,104			5,264,996
	Motor vehicles		435,182			424,958
	Total		21,316,243			20,765,612
	Less: Accumulated depreciation		(8,715,652	)		(7,476,960	)
	Construction-in-progress		112,372			-
	Property and equipment, net	$	12,712,963		$	13,288,652
	Construction-in-progress, as of September 30, 2013, includes leasehold improvements in progress for a new clinic under Jiuzhou Clinic.  No depreciation is provided for construction-in-progress until such time as the assets are completed and placed into service.
	Total depreciation expense for property and equipment was $512,065 and $645,543 for the three months ended September 30, 2013 and 2012, respectively, and $1,061,755 and $1,217,959 for the six months ended September 30, 2013 and 2012, respectively.

ADVANCES_TO_SUPPLIERS

ADVANCES TO SUPPLIERS	6 Months Ended
	Sep. 30, 2013
Advances To Suppliers [Abstract]	'
ADVANCES TO SUPPLIERS	'
	Note 7 – ADVANCES TO SUPPLIERS
	Advances to suppliers consist of deposits with or advances to outside vendors for future inventory purchases. Most of the Company’s vendors require a certain amount of money to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears no interest.  As of September 30, 2013 and March 31, 2013, advances to suppliers consisted of the following:
		September 30,			March 31,
		2013			2013
	Advance to suppliers	$	14,394,521		$	19,119,231
	Less: allowance for doubtful accounts		(3,323,872	)		(3,596,197	)
	Advance to suppliers, net	$	11,070,649		$	15,523,034
	For the three months ended September 30, 2013 and 2012, no advances to suppliers were written off against previous allowance for doubtful accounts. For the six months ended September 30, 2013 and 2012, $452,246 and $0 of advances to suppliers were written off against previous allowance for doubtful accounts, respectively.

LONG_TERM_DEPOSITS

LONG TERM DEPOSITS	6 Months Ended
	Sep. 30, 2013
Long Term Deposits [Abstract]	'
LONG TERM DEPOSITS	'
	Note 8 – LONG TERM DEPOSITS
	Long term deposits consist of the following:
			September 30,		March 31,
			2013		2013
	Long term rental deposit (1)		$	2,823,014	$	2,760,665
	Long term deposit for land use right (2)			1,361,303		-
	Total		$	4,184,317	$	2,760,665
	-1	Money deposited with or advanced to landlords for securing retail store leases for which the Company does not anticipate applying or being returned within the next twelve months. Most of the Company’s landlords require a minimum of nine months’ rent being paid upfront plus additional deposits.
	-2	Full prepayment for the purchase of land use right to a property planned as a TCM Plant. The Company has received the official land use right certificate on October 10, 2013, although construction has not begun.

OTHER_NONCURRENT_ASSETS

OTHER NONCURRENT ASSETS	6 Months Ended
	Sep. 30, 2013
Other Assets, Noncurrent Disclosure [Abstract]	'
OTHER NONCURRENT ASSETS	'
	Note 9 – OTHER NONCURRENT ASSETS
	Other noncurrent assets consisted of the following:
			September 30,		March 31,
			2013		2013
	Prepayment for lease of land use right – noncurrent (1)		$	5,460,500	$	5,419,600
	Lease rights transfer fees-noncurrent (2)			-		11,726
	Total		$	5,460,500	$	5,431,326
	-1	Payments made to a local government in connection with entering into a 30-year operating land lease agreement.
	-2	Lease rights transfer fees are paid by the Company to secure store rentals in coveted areas. These additional costs of acquiring the right to lease new store locations are capitalized and amortized over the period of the initial lease term.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	Note 10 – INTANGIBLE ASSETS
	Net intangible assets consisted of the following at:
		September 30,			March 31,
		2013			2013
	Licenses and permits		1,130,217			1,104,801
	Software		476,133			466,071
	Total other intangible assets		1,606,350			1,570,872
	Less: accumulated amortization		(456,369	)		(368,614	)
	Intangible assets, net	$	1,149,981		$	1,202,258
	Amortization expense of intangibles amounted to $39,584 and $38,766 for the three months ended September 30, 2013 and 2012, respectively, and $78,831 and $77,216 for the six months ended September 30, 2013 and 2012, respectively.

SHORTTERM_LOAN_PAYABLE

SHORT-TERM LOAN PAYABLE	6 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
SHORT-TERM LOAN PAYABLE	'
	Note 11 – SHORT-TERM LOAN PAYABLE
	As of September 30, 2013, short-term loan consists of a loan of $163,000 (RMB 1,000,000) from Industrial and Commercial Bank of China, due on May 9, 2014 with annual interest of 6.6%. This loan is guaranteed by Hangzhou SME Guarantee Co., Ltd., which is not related to or affiliated with the Company.

TAXES

TAXES	6 Months Ended
	Sep. 30, 2013
Tax Disclosure [Abstract]	'
TAXES	'
	Note 12 – TAXES
	Income tax
	The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled.
	Entity		Income Tax Jurisdiction
	Jo-Jo Drugstores		United States
	Renovation		Hong Kong
	All other entities		PRC
	The following table reconciles the U.S. statutory tax rates with the Company's effective tax rate for the three and six months ended September 30, 2013 and 2012:
			For the three months						For the six months
			ended September 30,						ended September 30,
			2013			2012			2013			2012
	U.S. Statutory rates			34	%		34	%		34	%		34	%
	Foreign income not recognized in the U.S.			(34.0	)		(34.0	)		(34.0	)		(34.0	)
	China income taxes			25			25			25			25
	Exemption rendered by local tax authorities  (1)			-			(25.0	)		-			(25.0	)
	Change in valuation allowance (2)			(32.1	)		-			(31.0	)		-
	Others (3)			(0.7	)		(0.0	)		(0.3	)		-0.4
	Effective tax rate			(7.8	)%		(0.0	)%		(6.3	)%		-0.4	%
	-1	Qianhong Agriculture enjoyed income tax waiver as an agriculture company since its start in 2010.
	-2	Certain subsidiaries incurred operating loss in the three and six months ended September 30, 2013.
	-3	Represent expenses incurred by the Company that were not deductible for PRC income tax.
	Jo-Jo Drugstores is incorporated in the U.S. and incurred a net operating loss for income tax purposes for three and six months ended September 30, 2013 and 2012.  As of September 30, 2013, the estimated net operating loss carryforwards for U.S. income tax purposes amounted to $1,409,000 which may be available to reduce future years’ taxable income.  These carryforwards will expire, if not utilized by 2031. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. income tax purposes.  Accordingly, the Company has provided a 100% valuation allowance at September 30, 2013.  The net change in the valuation allowance for the six months ended September 30, 2013 and 2012 was an increase of approximately $12,000 and $46,000, respectively Management reviews this valuation allowance periodically and makes adjustments as necessary.
	Taxes payable at September 30, 2013 and March 31, 2013 consisted of the following:
			September 30,			March 31,
			2013			2013
	VAT		$	314,455		$	334,833
	Income tax			54,634			7,628
	Others			10,892			29,172
	Total taxes payable		$	379,981		$	371,633

POSTRETIREMENT_BENEFITS

POSTRETIREMENT BENEFITS	6 Months Ended
	Sep. 30, 2013
Compensation and Retirement Disclosure [Abstract]	'
POSTRETIREMENT BENEFITS	'
	Note 13 – POSTRETIREMENT BENEFITS
	Regulations in the PRC require the Company to contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage of the employee’s current compensation as required by the local government. The Company contributed $176,883 and $81,799 in employment benefits and pension for the three months ended September 30, 2013 and 2012, respectively, and $321,947 and $245,945 for the six months ended September 30, 2013 and 2012, respectively.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	6 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	'
	Note 14 – RELATED PARTY TRANSACTIONS AND ARRANGEMENTS
	Amounts payable to related parties are summarized as follows:
			September 30,		March 31,
			2013		2013
	Due to cofounders (1):		$	576,818	$	576,818
	Due to director (2):			1,527,917		647,599
	Total		$	2,104,735	$	1,224,417
	-1	As of September 30, 2013 and March 31, 2013, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements.
	-2	Due to foreign exchange restrictions, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. In addition, Mr. Lei Liu lent about $600,000 to purchase a piece of land use right.
	As of September 30, 2013 and March 31, 2013, notes payable totaling $6,547,710 and $7,186,453 were secured by the personal properties of certain of the Company’s shareholders, respectively.
	The Company leases from Mr. Lei Liu a retail space which expires in August 2014, and its corporate office which expires in December 2013. Rent expense amounted to $48,702 and $46,770 for the three months ended September 30, 2013 and 2012, respectively, and $97,062 and $95,028 for the six months ended September 30, 2013 and 2012, respectively. Rent was accrued but not paid to Mr. Liu for the three and six months ended September 30, 2013 and 2012.

PURCHASE_OPTION_DERIVATIVE_LIA

PURCHASE OPTION DERIVATIVE LIABILITY	6 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
PURCHASE OPTION DERIVATIVE LIABILITY	'
	Note 15 – PURCHASE OPTION DERIVATIVE LIABILITY
	In connection with the public offering of the Company’s common stock that closed on April 28, 2010, the Company issued to its underwriters, Madison Williams and Company (“MWC”) and Rodman & Renshaw, LLC, an option for $100 to purchase up to a total of 105,000 shares of common stock (3% of the shares sold in the public offering) at $6.25 per share (125% of the price of the shares sold in the public offering). The option is exercisable commencing on October 23, 2010 and expires on April 22, 2015.
	The Company is treating the common shares underlying both options as a derivative liability as the strike price of the option is denominated in U.S. dollars, a currency other than the Company’s functional currency, the Chinese RMB. As a result, the option is not considered indexed to the Company’s own stock, and as such, all future changes in the fair value of the option are recognized currently in earnings until such time as the option is exercised or expired.
	On April 22, 2010, the issue date of MWC’s option, the Company classified the fair value of this option as a liability resulting in a decrease of additional paid-in capital of $402,451 and the establishment of a $402,451 in liability to recognize the option’s fair value. The Company recognized a loss of $1,036 from the change in fair value of the option liability for the three months ended September 30, 2013, and a gain of $11,629 for the six months ended September 30, 2013.The Company recognized a loss of $25,905 and $25,747 from the change in fair value of the option liability for the three and six months ended September 30, 2012, respectively.
	This option does not trade in an active securities market, and as such, the Company estimates its fair value using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”) on the date that the option was originally issued and as of September 30, 2013 using the following assumptions:
			Underwriter
			Purchase Option
			September 30,
			2013 (1)
	Stock price		$	0.7
	Exercise price		$	6.25
	Annual dividend yield			0	%
	Expected term (years)			1.55
	Risk-free interest rate			0.33	%
	Expected volatility			106.98	%
	-1	As of September 30, 2013, the option was not exercised.
	Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that correspond to the term of the option. The Company believes this method produces an estimate that is representative of future volatility over the expected term of this option. The expected life is based on the remaining term of the option. The risk-free interest rate is based on U.S. Treasury securities according to the remaining term of the option.
	Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Depending on the product and the terms of the transaction, the fair values of option liability are modeled using a series of techniques, including closed-form analytic formula such as the Black-Scholes Model, which does not entail material subjectivity because the methodology employed does not necessitate significant judgment, and the pricing inputs are observed from actively quoted markets.
	The fair value of the 105,000 shares underlying the option outstanding as of September 30, 2013 was determined using the Black-Scholes Model, with certain inputs significant to the valuation methodology as level 2 inputs, and the Company recorded the change in fair value in earnings. As a result, the option liability is carried on the consolidated balance sheets at fair value.

WARRANTS

WARRANTS	6 Months Ended
	Sep. 30, 2013
Warrants and Rights Note Disclosure [Abstract]	'
WARRANTS	'
	Note 16 – WARRANTS
	On September 26, 2013, as annual compensation for its financial advisory service, the Company issued common stock purchase warrant to a financial consulting firm to purchase up to a total of 150,000 stock purchases at $1.20 per share. The warrant is exercisable commencing on September 26, 2013 and expires on September 25, 2016.
	Because the warrant is denominated in U.S. dollars and the Company’s functional currency is the Renminbi, it does not meet the requirements of the accounting standard to be indexed only to the Company’s stock. Accordingly, it is accounted for at fair value as derivative liabilities and marked to market each period.
	The warrant does not trade in an active securities market, and as such, the Company estimates its fair value using the Black-Scholes Model on the date that the warrants were originally issued and as of September 30, 2013 using the following assumptions:
			Common Stock Warrants
			September 30,
			2013 (1)
	Stock price		$	0.7
	Exercise price		$	1.2
	Annual dividend yield			0	%
	Expected term (years)			2.99
	Risk-free interest rate			0.63	%
	Expected volatility			99.19	%
	-1	As of September 30, 2013, the warrants had not been exercised.
	On September 26, 2013, the issue date of the warrant, the Company classified its fair value as a liability resulting in an increase of prepaid service expense of $33,606 and the establishment of a $33,606 in liability to recognize the warrant’s fair value. The Company recognized a loss of $20,012 from the change in fair value of the warrant liability for the three and six months ended September 30, 2013.

STOCKHOLDERS_EQUITY

STOCKHOLDER'S EQUITY	6 Months Ended
	Sep. 30, 2013
Stockholders Equity Note [Abstract]	'
STOCKHOLDER'S EQUITY	'
	Note 17 – STOCKHOLDER’S EQUITY
	Stock-based compensation
	On August 1, 2011, the Company appointed Mr. Ming Zhao as its chief financial officer, and in connection therewith, entered into an agreement pursuant to which the Company agreed to issue him 40,000 shares of restricted common stock under the Company’s stock incentive plan (the “Plan”), to be vested in eight equal quarterly installments over two years. Mr. Zhao agreed to waive the remaining shares awards from November 1, 2012. The trading values of the Company’s common stock on August 1, 2011 were $1.70. Accordingly, $0 and $8,500 was charged to general and administrative expense for the three and six months ended September 30, 2013 and 2012, respectively.
	The Company agreed to issue 2,340 shares of common stock every six months to its legal counsel as partial payment for legal services. On May 1, 2012 and November 1, 2012, the Company agreed to issue additional 2,340 shares of common stock to its legal counsel as partial payment for two consecutive six months of legal services. The terms of the service agreement was continued on May 1, 2013, with 2,340 shares of restricted common stock to be issued accordingly. The trading value of the Company’s common stock on May 1, 2012, November 1, 2012 and May 1, 2013 was $1.07, $0.72 and $0.66, respectively. Accordingly, $772 and $1,252 was recorded as service compensation expense for the three months ended September 30, 2013 and 2012, respectively, and $1,563 and $2,719 for the six months ended September 30, 2013 and 2012, respectively.
	On January 16, 2012, the Company granted a total of 297,000 shares of restricted common stock under the Plan to a group of 46 employees. These restricted shares will vest on January 16, 2015, provided that the employees are still employed by the Company on such date. $19,612 and $7,226 were charged to general and administrative expense and selling expense, respectively, for the three months ended September 30, 2013, and $39,224 and $15,452 for the six months ended September 30, 2013, respectively. $19,612 and $7,190 were charged to general and administrative expense and selling expense respectively for the three months ended September 30, 2012, and $39,011 and $15,126 for the six months ended September 30, 2012, respectively.
	On September 26, 2013, the Company agreed to grant a total of 350,000 shares of restricted common stock to a financial consulting firm for its financial advisory services. The term of the service agreement is one year. The trading value of the Company’s common stock on September 26, 2013 was $0.51. For the three months and six months ended September 30, 2013, $2,445 was recorded as service compensation expense.
	Statutory reserve
	Statutory reserves represent restricted retained earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts on an annual basis to the Statutory Surplus Reserve Fund (the “Reserve Fund”). Once the total amount set aside in the Reserve Fund reaches 50% of the entity’s registered capital, further appropriations become discretionary. The Reserve Fund can be used to increase the entity’s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividend or otherwise, except in the event of liquidation.
	Appropriations to the Reserve Fund are accounted for as a transfer from unrestricted earnings to statutory reserves. During the three months ended September 30, 2013 and 2012, the Company did not make appropriations to the statutory reserves.
	There are no legal requirements in the PRC to fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.

EARNINGS_PER_SHARE

EARNINGS PER SHARE	6 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE	'
	Note 18 – EARNINGS PER SHARE
	The Company reports earnings per share in accordance with the provisions of the FASB’s related accounting standard. This standard requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution, but includes vested restricted stocks and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period.  Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.
	The following is a reconciliation of the basic and diluted earnings per share computation:
		Three months ended				Six months ended
		September 30,				September 30,
		2013		2012		2013		2012
	Net loss attributable to controlling interest	$	-546,590	$	-1,528,449	$	-1,333,578	$	-993,562
	Weighted average shares used in basic computation		13,609,003		13,588,569		13,609,003		13,575,550
	Diluted effect of purchase options and warrants		-		-		-		-
	Diluted effect of restricted shares		-		-		-		-
	Weighted average shares used in diluted computation		13,609,003		13,588,569		13,609,003		13,575,550
	Loss per share – Basic:
	Net loss before noncontrolling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07
	Add: Net loss attributable to noncontrolling interest	$	-	$	-	$	-	$	-
	Net loss attributable to controlling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07
	Loss per share – Diluted:
	Net loss before noncontrolling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07
	Add: Net loss attributable to noncontrolling interest	$	-	$	-	$	-	$	-
	Net loss attributable to controlling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07
	For the three and six months ended September 30, 2013 and 2012, both 105,000 and 150,000 shares underlying outstanding purchase options and warrants were excluded from the diluted earnings per share calculation as they are anti-dilutive.

SEGMENTS

SEGMENTS	6 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
SEGMENTS	'
	Note 19 – SEGMENTS
	The Company operates within three main reportable segments: retail drugstores, drug wholesale and herb farming.  The retail drugstores segment sells prescription and over-the-counter medicines, TCM, dietary supplement, medical devices, and sundry items to retail customers.  The drug wholesale segment includes supplying the Company’s own retail drugstores with prescription and over-the-counter medicines, TCM, dietary supplement, medical devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors and hospitals. The Company’s herb farming segment cultivates selected herbs for sales to other drug vendors. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable segments and are included in the retail drugstores segment.
	Each segment’s accounting policies are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest and income taxes not including nonrecurring gains and losses.
	The Company's reportable business segments are strategic business units that offer different products and services. Each segment is managed separately because they require different operation and markets to distinct classes of customers.
	The following table presents summarized information of the continuing operations by segment for the three months ended September 30, 2013:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	11,052,942		$	5,802,479		$	-		$	16,855,421
	Cost of goods		8,544,744			5,362,274			-			13,907,018
	Gross profit	$	2,508,198		$	440,205		$	-		$	2,948,403
	Selling expenses		1,574,104			1,405,027			-			2,979,131
	General and administrative expenses		1,264,804			(818,103)			45,280			491,981
	Loss from operations	$	(330,710	)	$	(146,719	)	$	(45,280)		$	(522,709)
	Depreciation and amortization	$	410,521		$	140,867		$	262		$	551,650
	Total capital expenditures	$	1,386,806		$	16,088		$	-		$	1,402,894
	Total assets	$	34,714,300		$	28,703,706		$	6,847,398		$	70,265,404
	The following table presents summarized information of the continuing operations by segment for the three months ended September 30, 2012:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	10,497,948		$	16,167,166		$	-		$	26,665,114
	Cost of goods		7,690,140			15,552,777			-			23,242,917
	Gross profit	$	2,807,808		$	614,389		$	-		$	3,422,197
	Selling expenses	$	2,044,728		$	57,893		$	-		$	2,102,621
	General and administrative expenses	$	1,300,179		$	(22,842	)	$	32,976		$	1,310,313
	(Loss) income from operations	$	(537,099	)	$	579,338		$	( 32,976	)	$	9,263
	Depreciation and amortization	$	568,012		$	116,000		$	297		$	684,309
	Total capital expenditures	$	268,772		$	2,088		$	-		$	270,860
	Total assets	$	47,349,821		$	34,269,871		$	6,625,406		$	88,245,098
	The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2013:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	21,965,332		$	10,226,608		$	-		$	32,191,940
	Cost of goods		16,672,215			8,970,153			-			25,642,368
	Gross profit	$	5,293,117		$	1,256,455		$	-		$	6,549,572
	Selling expenses		3,248,351			1,411,622						4,659,973
	General and administrative expenses		2,831,847			195,565			105,387			3,132,799
	Loss from operations	$	(787,081	)	$	(350,732	)	$	(105,387	)	$	(1,243,200	)
	Depreciation and amortization	$	867,839		$	272,225		$	522		$	1,140,586
	Total capital expenditures	$	1,503,514		$	17,424		$	-		$	1,520,938
	Total assets	$	34,714,300		$	28,703,706		$	6,847,398		$	70,265,404
	The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2012:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	19,452,405		$	37,535,949		$	2,524,091		$	59,512,445
	Cost of goods		14,319,144			36,396,678			229,649			50,945,471
	Gross profit	$	5,133,261		$	1,139,271		$	2,294,442		$	8,566,974
	Selling expenses		3,844,400		$	108,507		$	-		$	3,952,907
	General and administrative expenses		3,018,426		$	1,104,512		$	41,892		$	4,164,830
	(Loss) income from operations	$	(1,729,565	)	$	(73,748	)	$	2,252,550		$	449,237
	Depreciation and amortization	$	1,034,951		$	252,168		$	8,056		$	1,295,175
	Total capital expenditures	$	484,682		$	2,632		$	-		$	487,314
	Total assets	$	47,349,821		$	34,269,871		$	6,625,406		$	88,245,098
	The Company does not have long-lived assets located outside the PRC.  In accordance with the enterprise-wide disclosure requirements of FASB’s accounting standard, the Company's net revenue from external customers through its retail stores by main products is as follows:
		Three months ended						Six months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Prescription drugs	$	4,637,114		$	4,304,562		$	9,924,263		$	8,334,655
	Over-the-counter drugs		4,089,736			3,111,558			8,015,176			5,737,825
	Nutritional supplements		647,177			1,713,605			1,207,014			2,542,891
	Traditional Chinese medicine		907,267			935,439			1,428,513			1,802,140
	Sundry products		473,882			173,814			771,174			396,753
	Medical devices		297,766			258,970			619,192			628,141
	Total	$	11,052,942		$	10,497,948		$	21,965,332		$	19,452,405
The Company’s net revenue from external customers through wholesale by main products is as follows:
	Three months ended						Six months ended
	September 30,						September 30,
	2013			2012			2013			2012
Prescription drugs	$	4,276,822		$	8,404,741		$	7,649,675		$	21,125,002
Over-the-counter drugs		96,125			3,318,318			875,345			7,851,391
Nutritional supplements		875			4,231,039			261,130			8,339,633
Traditional Chinese medicine		-			210,921			927			213,787
Sundry products		1,428,657			901			1,432,811			1,983
Medical devices		-			1,246			6,720			4,153
Total	$	5,802,479		$	16,167,166		$	10,226,608		$	37,535,949
The Company’s net revenue from external customers through herb farming by main products is as follows:
	Three months ended						Six months ended
	September 30,						September 30,
	2013			2012			2013			2012
Prescription drugs	$	-		$	-		$	-		$	-
Over-the-counter drugs		-			-			-			-
Nutritional supplements		-			-			-			-
Traditional Chinese medicine		-			-			-			2,524,091
Sundry products		-			-			-			-
Medical devices		-			-			-			-
Total	$	-		$	-		$	-		$	2,524,091

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	Note 20 – COMMITMENTS AND CONTINGENCIES
	Operating lease commitments
	The Company recognizes lease expense on a straight line basis over the term of its leases in accordance with the relevant accounting standards. The Company has entered into various tenancy agreements for its store premises and for the land leased from a local government to farm herbs.
	The Company’s commitments for minimum rental payments under its leases for the next five years and thereafter are as follows:
	Periods ending September 30,	Retail		Drug		Herb farming		Total
		drugstores		wholesale				Amount
	2014	$	2,417,962	$	239,143	$	-	$	2,657,105
	2015		658,704		271,580		-		930,284
	2016		259,673		288,915		-		548,588
	2017		132,476		288,915		-		421,391
	2018		55,693		288,915		-		344,608
	Thereafter		19,203		320,695		-		339,718
	Total rent expense amounted to $923,572 and $1,218,696 for the three months ended September 30, 2013 and 2012, respectively, and $1,889,150 and $2,250,441 for the six months ended September 30, 2013 and 2012, respectively.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of presentation and consolidation	'
	Basis of presentation and consolidation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“US GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. These condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2013 filed with the SEC on July 1, 2013. Operating results for the three and six months ended September 30, 2013 may not be necessarily indicative of the results that may be expected for the full year.
	The condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and VIEs.  All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.
Consolidation of variable interest entities	'
	Consolidation of variable interest entities
	In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes.
	The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns.
	Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements.
	Control and common control is defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized the Voting Rights Proxy Agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company.
Risks and Uncertainties	'
	Risks and Uncertainties
	The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.
	The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its vendors or landlords.
	Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC.  The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns.  As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs.
Use of estimates	'
	Use of estimates
	The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable and related allowance for doubtful accounts, useful lives of property and equipment, and fair value of purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.
Intangibles	'
	Intangibles
	Intangible assets, whether acquired individually or as part of a group of assets, are initially recorded at their fair value.  The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values.
	The estimated useful lives of the Company’s intangible assets are as follows:
		Estimated Useful Life
	Licenses and permits	Indefinite
	Software	3 years
	The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired.
	There was no intangible impairment during the three and six months ended September 30, 2013.
Revenue recognition	'
	Revenue recognition
	Revenue from sales of prescription medicine at the drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription.
	Revenue from sales of other merchandise at the drugstores is recognized at the point of sale, which is when the customer pays for and receives the merchandise.
	Revenue from medical services is recognized after the service has been rendered to the customer.
	Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal.
	The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.
Restricted cash	'
	Restricted cash
	The Company’s restricted cash consists of cash in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.
Accounts receivable	'
	Accounts receivable
	Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, and (3) amounts due from non-retail customers for sales of merchandise.
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate.
	In its retail business, accounts receivable mainly consist of reimbursements due from government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which is determined to be uncollectable after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trend.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined using the first in first out (FIFO) method. Market is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at its purchase price, which includes direct cost such as seed selection, fertilizer, labor costs and contract fee that are spent in growing herbs on the leased farmland, and indirect cost which includes amortization of farmland development cost. All the costs are accumulated until the time of harvest and then allocated to harvested herbs upon sales. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified.  Historically, these amounts have not been material to the consolidated financial statements.
Property and equipment	'
	Property and equipment
	Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment:
		Estimated Useful Life
	Leasehold improvements	3-10 years
	Motor vehicles	5 years
	Office equipment & furniture	3-5 years
	Buildings	10 years
	Maintenance, repairs and minor renewals are charged to expense as incurred. Major additions and betterment to property and equipment are capitalized.
Impairment of long lived assets	'
	Impairment of long lived assets
	The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There was no impairment of these assets as of September 30, 2013.
Notes payable	'
	Notes payable
	During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months.
Income taxes	'
	Income taxes
	The Company records income taxes pursuant to the accounting standards for income taxes. These standards require the recognition of deferred income tax liabilities and assets for the expected future tax consequences of temporary differences between income tax basis and financial reporting basis of assets and liabilities. Provision for income taxes consists of taxes currently due and the net change in deferred taxes.  A valuation allowance is recognized if it is more likely than not that some portion, or all of, a deferred tax asset will not be realized.
Stock based compensation	'
	Stock based compensation
	The Company follows the provisions of ASC 718, “Compensation — Stock Compensation,” which establishes the accounting for non-employee and employee stock-based awards. Under the provisions of ASC 718, the fair value of the stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award.
Advertising and promotion costs	'
	Advertising and promotion costs
	Advertising and promotion costs are expensed as incurred and amounted to $18,632 and $36,886 for three months ended September 30, 2013 and 2012, respectively, and $56,533 and $75,139 for the six months ended September 30, 2013 and 2012, respectively. Such costs consist primarily of print and television advertisements.
Foreign currency translation	'
	Foreign currency translation
	The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC.
	In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income.
	The balance sheet amounts, with the exception of equity, at September 30, 2013 and March 31, 2013 were translated at 1 RMB to $0.1630 USD and at 1 RMB to $0.1594 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2013 and 2012 were at 1 RMB to $0.1618 USD and at 1 RMB to $0.1580 USD, respectively.
Concentrations and credit risk	'
	Concentrations and credit risk
	Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Balances at financial institutions and state-owned banks within the PRC are not covered by insurance. As of September 30, 2013 and March 31, 2013, the Company had deposits totaling $7,912,547 and $6,230,011 that were not covered by insurance, respectively. To date, the Company has not experienced any losses in such accounts.
	For the three months ended September 30, 2013, no vendor accounted for more than 10% of the Company’s total purchases and one vendor accounted for 20% of total advances to suppliers. For the three months ended September 30, 2012, one vendor accounted for approximately 12% of the Company’s total purchases and another vendor accounted for 22% of total advances to suppliers.
	For the six months ended September 30, 2013, one vendor accounted for 10% of the Company’s total purchases and another vendor accounted for 20% of total advances to suppliers. For the six months ended September 30, 2012, one vendor accounted for approximately 13% of the Company’s total purchases and another vendor accounted for 22% of total advances to suppliers.
	For the three months ended September 30, 2013, no customer accounted for more than 10% of the Company’s total sales and one customer accounted for 12% of total accounts receivable. For the three months ended September 30, 2012, one customer accounted for approximately 16% of the Company’s total sales and another customer accounted for 15% of total accounts receivable.
	For the six months ended September 30, 2013, no customer accounted for more than 10% of the Company’s total sales, and one customer accounted for 12% of total accounts receivable. For the six months ended September 30, 2012, one customer accounted for approximately 14% of the Company’s total sales and another customer accounted for 15% of total accounts receivable.
Noncontrolling interest	'
	Noncontrolling interest
	As of September 30, 2013, 1% of the equity interests of Shanghai Zhongxing was owned by Shanghai Bieyanghong Grand Pharmacy Co., Ltd. and not under the Company's control.

DESCRIPTION_OF_BUSINESS_AND_OR1

DESCRIPTION OF BUSINESS AND ORGANIZATION (Tables)	6 Months Ended
	Sep. 30, 2013
Description Of Business and Organization [Abstract]	'
Schedule of activities of company and affiliates	'
	Entity Name		Background	Ownership
	Renovation HK		● Incorporated in Hong Kong SAR on September 2, 2008	100%
	Jiuxin Management		● Established in the PRC on October 14, 2008	100%
			● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law
			● Registered capital of $4.5 million fully paid
	Shouantang Technology		● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million	100%
			● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid
			● Deemed a WFOE under PRC law
			● Invests and finances the working capital of Quannuo Technology
	Qianhong Agriculture		● Established in the PRC on August 10, 2010 by Jiuxin Management	100%
			● Registered capital of RMB 10 million fully paid
			● Carries out herb farming business
	Quannuo Technology		● Established in the PRC on July 7, 2009	100%
			● Registered capital of RMB 10 million fully paid
			● Acquired by Shouantang Technology in November 2010
			● Operates the Company’s online pharmacy website and provide software and technical support
	Hangzhou Quannuo		● Established in the PRC on July 8, 2010 by Quannuo Technology	100%
			● Registered capital of RMB 800,000 fully paid
			● Currently has no operation
	Jiuzhou Pharmacy (1)		● Established in the PRC on September 9, 2003	VIE by contractual  arrangements (2)
			● Registered capital of RMB 5 million fully paid
			● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou
	Jiuzhou Clinic (1)		● Established in the PRC as a general partnership on October 10, 2003	VIE by contractual arrangements (2)
			● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores
	Jiuzhou Service (1)		● Established in the PRC on November 2, 2005	VIE by contractual  arrangements (2)
			● Registered capital of RMB 500,000 fully paid
			● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores
	Shanghai Lydia		● Established in the PRC on January 31, 2011 by Jiuzhou Pharmacy	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)
			● Registered capital of RMB 1 million fully paid
			● Operates the “Lydia Grand Pharmacy” and “Chaling Grand Pharmacy”  stores in Shanghai
	Jiuxin Medicine		● Established in PRC on December 31, 2003	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)
			● Acquired by Jiuzhou Pharmacy in August 2011
			● Registered capital of RMB 10 million fully paid
			● Carries out pharmaceutical distribution services
	Shanghai Zhongxing		● Established in PRC on June 19, 2006	VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia (2)
			● Registered capital of RMB 1 million fully paid
			● 99% acquired by Shanghai Lydia in July 2011
			● Operates the “Zhongxing Grand Pharmacy” store in Shanghai
	Lydia Trading		● Established in the PRC on June 20, 2012 with registered capital of RMB 1 million fully paid	VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia (2)
			● Operates one “Weifang Grand Pharmacy” store in Shanghai
	Shanghai Zhenguang		● Established in the PRC on October 31, 2012 with registered capital of RMB 500,000 fully paid	VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia (2)
			● Operates the “Zhenguang Grand Pharmacy” store in Shanghai
	Jiutong Medical		● Established in the PRC on December 20, 2011 by Renovation with registered capital of $5 million	100%
			● $2.6 million of registered capital paid, with the remaining $2.4 million due by December 20, 2013
			● Currently has no operation
	-1	Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of their three cofounders (the “Owners”) since their respective establishment dates, pursuant to agreements amongst the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies in accordance with generally accepted accounting standards. Operationally, the Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Shanghai Lydia, Shanghai Zhongxing, Lydia Trading, Shanghai Zhenguang and Jiuxin Medicine are also deemed under the common control of the Owners as they are each a subsidiary of Jiuzhou Pharmacy.
	-2	To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as the two subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries and entity under the control of Jiuzhou Pharmacy (Shanghai Lydia, Jiuxin Medicine, Shanghai Zhongxing, Lydia Trading and Shanghai Zhenguang), are consolidated into the financial statements of the Company.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of estimated useful lives of intangible assets	'
		Estimated Useful Life
	Licenses and permits	Indefinite
	Software	3 years
Schedule of estimated useful lives of property and equipment	'
		Estimated Useful Life
	Leasehold improvements	3-10 years
	Motor vehicles	5 years
	Office equipment & furniture	3-5 years
	Buildings	10 years

TRADE_ACCOUNTS_RECEIVABLE_Tabl

TRADE ACCOUNTS RECEIVABLE (Tables)	6 Months Ended
	Sep. 30, 2013
Accounts Receivable, Net [Abstract]	'
Schedule of trade accounts receivable	'
		September 30,			March 31,
		2013			2013
	Accounts receivable	$	17,179,460		$	18,007,051
	Less: allowance for doubtful accounts		(4,487,830	)		(5,028,243	)
	Trade accounts receivable, net	$	12,691,630		$	12,978,808

OTHER_CURRENT_ASSETS_Tables

OTHER CURRENT ASSETS (Tables)	6 Months Ended
	Sep. 30, 2013
Other Current Assets [Abstract]	'
Schedule of other current assets	'
			September 30,		March 31,
			2013		2013
	Prepaid rental expenses		$	1,730,847	$	647,489
	Lease rights transfer fees (1)			72,916		247,789
	Prepaids and other current assets			337,039		326,221
	Total		$	2,140,802	$	1,221,499
	-1	Lease rights transfer fees are paid by the Company to secure store rentals in coveted areas. These additional costs of acquiring the right to lease new store locations are capitalized and amortized over the period of the initial lease term.

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of property and equipment	'
		September 30,			March 31,
		2013			2013
	Building	$	1,144,326		$	1,119,053
	Leasehold improvements		14,298,631			13,956,605
	Office equipment and furniture		5,438,104			5,264,996
	Motor vehicles		435,182			424,958
	Total		21,316,243			20,765,612
	Less: Accumulated depreciation		(8,715,652	)		(7,476,960	)
	Construction-in-progress		112,372			-
	Property and equipment, net	$	12,712,963		$	13,288,652

ADVANCES_TO_SUPPLIERS_Tables

ADVANCES TO SUPPLIERS (Tables)	6 Months Ended
	Sep. 30, 2013
Advances To Suppliers [Abstract]	'
Schedule of advance to suppliers	'
		September 30,			March 31,
		2013			2013
	Advance to suppliers	$	14,394,521		$	19,119,231
	Less: allowance for doubtful accounts		(3,323,872	)		(3,596,197	)
	Advance to suppliers, net	$	11,070,649		$	15,523,034

LONG_TERM_DEPOSITS_Tables

LONG TERM DEPOSITS (Tables)	6 Months Ended
	Sep. 30, 2013
Long Term Deposits [Abstract]	'
Schedule of Long Term Deposits	'
			September 30,		March 31,
			2013		2013
	Long term rental deposit (1)		$	2,823,014	$	2,760,665
	Long term deposit for land use right (2)			1,361,303		-
	Total		$	4,184,317	$	2,760,665
	-1	Money deposited with or advanced to landlords for securing retail store leases for which the Company does not anticipate applying or being returned within the next twelve months. Most of the Company’s landlords require a minimum of nine months’ rent being paid upfront plus additional deposits.
	-2	Full prepayment for the purchase of land use right to a property planned as a TCM Plant. The Company has received the official land use right certificate on October 10, 2013, although construction has not begun.

OTHER_NONCURRENT_ASSETS_Tables

OTHER NONCURRENT ASSETS (Tables)	6 Months Ended
	Sep. 30, 2013
Other Assets, Noncurrent Disclosure [Abstract]	'
Schedule of other noncurrent assets	'
			September 30,		March 31,
			2013		2013
	Prepayment for lease of land use right – noncurrent (1)		$	5,460,500	$	5,419,600
	Lease rights transfer fees-noncurrent (2)			-		11,726
	Total		$	5,460,500	$	5,431,326
	-1	Payments made to a local government in connection with entering into a 30-year operating land lease agreement.
	-2	Lease rights transfer fees are paid by the Company to secure store rentals in coveted areas. These additional costs of acquiring the right to lease new store locations are capitalized and amortized over the period of the initial lease term

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of net intangible assets	'
		September 30,			March 31,
		2013			2013
	Licenses and permits		1,130,217			1,104,801
	Software		476,133			466,071
	Total other intangible assets		1,606,350			1,570,872
	Less: accumulated amortization		(456,369	)		(368,614	)
	Intangible assets, net	$	1,149,981		$	1,202,258

TAXES_Tables

TAXES (Tables)	6 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Schedule of income arising in or derived from tax jurisdiction in which each entity is domiciled	'
	Entity		Income Tax Jurisdiction
	Jo-Jo Drugstores		United States
	Renovation		Hong Kong
	All other entities		PRC
Schedule of reconciles the U.S. statutory tax rates with company's effective tax rate	'
			For the three months						For the six months
			ended September 30,						ended September 30,
			2013			2012			2013			2012
	U.S. Statutory rates			34	%		34	%		34	%		34	%
	Foreign income not recognized in the U.S.			(34.0	)		(34.0	)		(34.0	)		(34.0	)
	China income taxes			25			25			25			25
	Exemption rendered by local tax authorities  (1)			-			(25.0	)		-			(25.0	)
	Change in valuation allowance (2)			(32.1	)		-			(31.0	)		-
	Others (3)			(0.7	)		(0.0	)		(0.3	)		(0.4	)
	Effective tax rate			(7.8	)%		(0.0	)%		(6.3	)%		-0.4	%
	-1	Qianhong Agriculture enjoyed income tax waiver as an agriculture company since its start in 2010.
	-2	Certain subsidiaries incurred operating loss in the three and six months ended September 30, 2013.
	-3	Represent expenses incurred by the Company that were not deductible for PRC income tax.
Schedule of taxes payable	'
			September 30,			March 31,
			2013			2013
	VAT		$	314,455		$	334,833
	Income tax			54,634			7,628
	Others			10,892			29,172
	Total taxes payable		$	379,981		$	371,633

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Tables)	6 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Schedule of amounts payable to related parties	'
			September 30,		March 31,
			2013		2013
	Due to cofounders (1):		$	576,818	$	576,818
	Due to director (2):			1,527,917		647,599
	Total		$	2,104,735	$	1,224,417
	-1	As of September 30, 2013 and March 31, 2013, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements.
	-2	Due to foreign exchange restrictions, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. In addition, Mr. Lei Liu lent about $600,000 to purchase a piece of land use right.

PURCHASE_OPTION_DERIVATIVE_LIA1

PURCHASE OPTION DERIVATIVE LIABILITY (Tables)	6 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of fair value assumption using Black-Scholes Option Pricing Model	'
			Underwriter
			Purchase Option
			September 30,
			2013 (1)
	Stock price		$	0.7
	Exercise price		$	6.25
	Annual dividend yield			0	%
	Expected term (years)			1.55
	Risk-free interest rate			0.33	%
	Expected volatility			106.98	%
	-1	As of September 30, 2013, the option was not exercised.

WARRANTS_Tables

WARRANTS (Tables)	6 Months Ended
	Sep. 30, 2013
Warrants and Rights Note Disclosure [Abstract]	'
Schedule of estimated fair value of warrants	'
			Common Stock Warrants
			September 30,
			2013 (1)
	Stock price		$	0.7
	Exercise price		$	1.2
	Annual dividend yield			0	%
	Expected term (years)			2.99
	Risk-free interest rate			0.63	%
	Expected volatility			99.19	%
	-1	As of September 30, 2013, the warrants had not been exercised.

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	6 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of reconciliation of the basic and diluted earnings per share computation	'
		Three months ended				Six months ended
		September 30,				September 30,
		2013		2012		2013		2012
	Net loss attributable to controlling interest	$	-546,590	$	-1,528,449	$	-1,333,578	$	-993,562
	Weighted average shares used in basic computation		13,609,003		13,588,569		13,609,003		13,575,550
	Diluted effect of purchase options and warrants		-		-		-		-
	Diluted effect of restricted shares		-		-		-		-
	Weighted average shares used in diluted computation		13,609,003		13,588,569		13,609,003		13,575,550
	Loss per share – Basic:
	Net loss before noncontrolling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07
	Add: Net loss attributable to noncontrolling interest	$	-	$	-	$	-	$	-
	Net loss attributable to controlling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07
	Loss per share – Diluted:
	Net loss before noncontrolling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07
	Add: Net loss attributable to noncontrolling interest	$	-	$	-	$	-	$	-
	Net loss attributable to controlling interest	$	-0.04	$	-0.11	$	-0.1	$	-0.07

SEGMENTS_Tables

SEGMENTS (Tables)	6 Months Ended
	Sep. 30, 2013
Segment Reporting Information [Line Items]	'
Schedule of information by segment	'
	The following table presents summarized information of the continuing operations by segment for the three months ended September 30, 2013:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	11,052,942		$	5,802,479		$	-		$	16,855,421
	Cost of goods		8,544,744			5,362,274			-			13,907,018
	Gross profit	$	2,508,198		$	440,205		$	-		$	2,948,403
	Selling expenses		1,574,104			1,405,027			-			2,979,131
	General and administrative expenses		1,264,804			(818,103)			45,280			491,981
	Loss from operations	$	(330,710	)	$	(146,719	)	$	(45,280)		$	(522,709)
	Depreciation and amortization	$	410,521		$	140,867		$	262		$	551,650
	Total capital expenditures	$	1,386,806		$	16,088		$	-		$	1,402,894
	Total assets	$	34,714,300		$	28,703,706		$	6,847,398		$	70,265,404
	The following table presents summarized information of the continuing operations by segment for the three months ended September 30, 2012:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	10,497,948		$	16,167,166		$	-		$	26,665,114
	Cost of goods		7,690,140			15,552,777			-			23,242,917
	Gross profit	$	2,807,808		$	614,389		$	-		$	3,422,197
	Selling expenses	$	2,044,728		$	57,893		$	-		$	2,102,621
	General and administrative expenses	$	1,300,179		$	(22,842	)	$	32,976		$	1,310,313
	(Loss) income from operations	$	(537,099	)	$	579,338		$	( 32,976	)	$	9,263
	Depreciation and amortization	$	568,012		$	116,000		$	297		$	684,309
	Total capital expenditures	$	268,772		$	2,088		$	-		$	270,860
	Total assets	$	47,349,821		$	34,269,871		$	6,625,406		$	88,245,098
	The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2013:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	21,965,332		$	10,226,608		$	-		$	32,191,940
	Cost of goods		16,672,215			8,970,153			-			25,642,368
	Gross profit	$	5,293,117		$	1,256,455		$	-		$	6,549,572
	Selling expenses		3,248,351			1,411,622						4,659,973
	General and administrative expenses		2,831,847			195,565			105,387			3,132,799
	Loss from operations	$	(787,081	)	$	(350,732	)	$	(105,387	)	$	(1,243,200	)
	Depreciation and amortization	$	867,839		$	272,225		$	522		$	1,140,586
	Total capital expenditures	$	1,503,514		$	17,424		$	-		$	1,520,938
	Total assets	$	34,714,300		$	28,703,706		$	6,847,398		$	70,265,404
	The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2012:
		Retail			Drug			Herb			Total
		drugstores			wholesale			farming
	Revenue	$	19,452,405		$	37,535,949		$	2,524,091		$	59,512,445
	Cost of goods		14,319,144			36,396,678			229,649			50,945,471
	Gross profit	$	5,133,261		$	1,139,271		$	2,294,442		$	8,566,974
	Selling expenses		3,844,400		$	108,507		$	-		$	3,952,907
	General and administrative expenses		3,018,426		$	1,104,512		$	41,892		$	4,164,830
	(Loss) income from operations	$	(1,729,565	)	$	(73,748	)	$	2,252,550		$	449,237
	Depreciation and amortization	$	1,034,951		$	252,168		$	8,056		$	1,295,175
	Total capital expenditures	$	484,682		$	2,632		$	-		$	487,314
	Total assets	$	47,349,821		$	34,269,871		$	6,625,406		$	88,245,098
Retail drugstores	'
Segment Reporting Information [Line Items]	'
Schedule of net revenue from external customers by main products	'
		Three months ended						Six months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Prescription drugs	$	4,637,114		$	4,304,562		$	9,924,263		$	8,334,655
	Over-the-counter drugs		4,089,736			3,111,558			8,015,176			5,737,825
	Nutritional supplements		647,177			1,713,605			1,207,014			2,542,891
	Traditional Chinese medicine		907,267			935,439			1,428,513			1,802,140
	Sundry products		473,882			173,814			771,174			396,753
	Medical devices		297,766			258,970			619,192			628,141
	Total	$	11,052,942		$	10,497,948		$	21,965,332		$	19,452,405
Drug wholesale	'
Segment Reporting Information [Line Items]	'
Schedule of net revenue from external customers by main products	'
		Three months ended						Six months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Prescription drugs	$	4,276,822		$	8,404,741		$	7,649,675		$	21,125,002
	Over-the-counter drugs		96,125			3,318,318			875,345			7,851,391
	Nutritional supplements		875			4,231,039			261,130			8,339,633
	Traditional Chinese medicine		-			210,921			927			213,787
	Sundry products		1,428,657			901			1,432,811			1,983
	Medical devices		-			1,246			6,720			4,153
	Total	$	5,802,479		$	16,167,166		$	10,226,608		$	37,535,949
Chinese herbs Farming	'
Segment Reporting Information [Line Items]	'
Schedule of net revenue from external customers by main products	'
		Three months ended						Six months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Prescription drugs	$	-		$	-		$	-		$	-
	Over-the-counter drugs		-			-			-			-
	Nutritional supplements		-			-			-			-
	Traditional Chinese medicine		-			-			-			2,524,091
	Sundry products		-			-			-			-
	Medical devices		-			-			-			-
	Total	$	-		$	-		$	-		$	2,524,091

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of company's commitments for minimum rental payments	'
	Periods ending September 30,	Retail		Drug		Herb farming		Total
		drugstores		wholesale				Amount
	2014	$	2,417,962	$	239,143	$	-	$	2,657,105
	2015		658,704		271,580		-		930,284
	2016		259,673		288,915		-		548,588
	2017		132,476		288,915		-		421,391
	2018		55,693		288,915		-		344,608
	Thereafter		19,203		320,695		-		339,718

DESCRIPTION_OF_BUSINESS_AND_OR2

DESCRIPTION OF BUSINESS AND ORGANIZATION - Summary of consolidated financial statements of various entities (Details)

6 Months Ended

6 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 16, 2010

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Renovation HK

Jiuxin Management

Shouantang Technology

Shouantang Technology

Qianhong Agriculture

Quannuo Technology

Hangzhou Quannuo

Jiuzhou Pharmacy

Jiuzhou Clinic

Jiuzhou Service

Shanghai Lydia

Jiuxin Medicine

Shanghai Zhongxing

Lydia Trading

Shanghai Zhenguang

Jiutong Medical

USD ($)

USD ($)

USD ($)

CNY

CNY

CNY

CNY

CNY

CNY

CNY

CNY

CNY

CNY

USD ($)

Schedule Of Activities Of Company and Affiliates [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership held in subsidiary

100.00%

100.00%

100.00%

'

100.00%

100.00%

100.00%

'

'

'

'

'

'

'

'

100.00%

Registered capital

'

$4,500,000

$11,000,000

'

10,000,000

10,000,000

800,000

5,000,000

[1]

'

500,000

[1]

1,000,000

10,000,000

1,000,000

1,000,000

500,000

$5,000,000

Renovation with registered capital

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Registered and paid - up capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,600,000

Description of background of entities

'

'

'

'

'

'

'

'

[1]

'

[1]

'

[1]

'

'

'

'

'

'

● Established in the PRC on October 14, 2008

● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million

● Established in the PRC on August 10, 2010 by Jiuxin Management

● Established in the PRC on July 7, 2009

● Established in the PRC on July 8, 2010 by Quannuo Technology

● Established in the PRC on September 9, 2003

● Established in the PRC as a general partnership on October 10, 2003

● Established in the PRC on November 2, 2005

● Established in the PRC on January 31, 2011 by Jiuzhou Pharmacy

● Established in PRC on December 31, 2003

● Established in PRC on June 19, 2006

● Established in the PRC on June 20, 2012 with registered capital of RMB 1 million fully paid

● Established in the PRC on October 31, 2012 with registered capital of RMB 500,000 fully paid

● Established in the PRC on December 20, 2011 by Renovation with registered capital of $5 million

● Incorporated in Hong Kong SAR on September 2, 2008

● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law

● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid

● Registered capital of RMB 10 million fully paid

● Registered capital of RMB 10 million fully paid

● Registered capital of RMB 800,000 fully paid

● Registered capital of RMB 5 million fully paid

● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores

● Registered capital of RMB 500,000 fully paid

● Registered capital of RMB 1 million fully paid

● Acquired by Jiuzhou Pharmacy in August 2011

● Registered capital of RMB 1 million fully paid

● Operates one “Weifang Grand Pharmacy” store in Shanghai

● Operates the “Zhenguang Grand Pharmacy” store in Shanghai

● $2.6 million of registered capital paid, with the remaining $2.4 million due by December 20, 2013

● Registered capital of $4.5 million fully paid

● Deemed a WFOE under PRC law

● Carries out herb farming business

● Acquired by Shouantang Technology in November 2010

● Currently has no operation

● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou

● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores

● Operates the “Lydia Grand Pharmacy” and “Chaling Grand Pharmacy”  stores in Shanghai

● Registered capital of RMB 10 million fully paid

● 99% acquired by Shanghai Lydia in July 2011

● Currently has no operation

● Invests and finances the working capital of Quannuo Technology

● Operates the Company’s online pharmacy website and provide software and technical support

● Carries out pharmaceutical distribution services

● Operates the “Zhongxing Grand Pharmacy” store in Shanghai

Description of ownership percentage of entities

'

'

'

'

'

'

'

'

[1],[2]

'

[1],[2]

'

[1],[2]

'

'

[2]

'

[2]

'

[2]

'

[2]

'

VIE by contractual arrangements

VIE by contractual arrangements

VIE by contractual arrangements

VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy

VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy

VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia

VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia

VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy through Shanghai Lydia

Unpaid capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,400,000

Percentage of ownership held in subsidiary by Shanghai Lydia

'

'

'

'

'

'

'

'

'

'

'

'

99.00%

'

'

'

[1]

Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of their three cofounders (the "Owners") since their respective establishment dates, pursuant to agreements amongst the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies in accordance with generally accepted accounting standards. Operationally, the Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Shanghai Lydia, Shanghai Zhongxing, Lydia Trading, Shanghai Zhenguang and Jiuxin Medicine are also deemed under the common control of the Owners as they are each a subsidiary of Jiuzhou Pharmacy.

[2]

To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as the two subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries and entity under the control of Jiuzhou Pharmacy (Shanghai Lydia, Jiuxin Medicine, Shanghai Zhongxing, Lydia Trading and Shanghai Zhenguang), are consolidated into the financial statements of the Company.

DESCRIPTION_OF_BUSINESS_AND_OR3

DESCRIPTION OF BUSINESS AND ORGANIZATION (Detail Textuals) (Renovation HK, Common Stock)	1 Months Ended
	Sep. 17, 2009
Renovation HK | Common Stock	'
Business Acquisition [Line Items]	'
Issuance of equity consideration (in shares)	7,900,000
Percentage of capital stock in exchange transaction	100.00%

DESCRIPTION_OF_BUSINESS_AND_OR4

DESCRIPTION OF BUSINESS AND ORGANIZATION (Detail Textuals 1)	6 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	31-May-12
	Cofounder	Shanghai Lydia	Shanghai Zhongxing	Jiuzhou Clinic	Shanghai Zhenguang	Hangzhou Quannuo
		Store	Store	Clinic	Store	Store
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Number of drugstores operated	'	2	1	'	1	1
Number of medical clinics owned	'	'	'	4	'	'
Number of cofounders	3	'	'	'	'	'

LIQUIDITY_Detail_Textuals

LIQUIDITY (Detail Textuals) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Jiuzhou Pharmacy	'
Line of Credit Facility [Line Items]	'
Increase in accounts payable	$5.70
Loan and Collateral Agreement | Local Bank	'
Line of Credit Facility [Line Items]	'
Pledged of assets for debt financing	5.3
Bank facilities available for future borrowing	$3.90

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of estimated useful lives of intangible assets (Details)	6 Months Ended
	Sep. 30, 2013
Licenses and permits	'
Intangible Assets [Line Items]	'
Estimated Useful Life	'Indefinite
Software	'
Intangible Assets [Line Items]	'
Estimated Useful Life	'3 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of estimated useful lives of property and equipment (Details 1)	6 Months Ended
	Sep. 30, 2013
Leasehold improvements	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life	'3-10 years
Motor vehicles	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life	'5 years
Office equipment & furniture	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life	'3-5 years
Buildings	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life	'10 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2012	Mar. 31, 2013	Mar. 31, 2013
	USD ($)	USD ($)	USD ($)	CNY	USD ($)	CNY	USD ($)	CNY
Accounting Policies [Abstract]	'	'	'	'	'	'	'	'
Benchmark percentage of the voting ownership interest for control and common control	'	'	50.00%	50.00%	'	'	'	'
Percentage of collectively owned variable interest entities	'	'	100.00%	100.00%	'	'	'	'
Advertising and promotion costs	$18,632	$36,886	$56,533	'	$75,139	'	'	'
Foreign currency exchange rate for translated amounts with exception of equity for balance sheet	$0.16	'	$0.16	1	'	'	$0.16	1
Average translation rates applied to income and cash flow statement amounts	'	'	$0.16	1	$0.16	1	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 1) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
			Supplier Concentration Risk	Supplier Concentration Risk	Supplier Concentration Risk	Supplier Concentration Risk	Supplier Concentration Risk	Supplier Concentration Risk	Supplier Concentration Risk
			Total purchases	Total purchases	Total purchases	Advances	Advances	Advances	Advances
			Vendor	Vendor	Vendor	Vendor	Store	Vendor	Vendor
Concentration Risk [Line Items]	'	'	'	'	'	'	'	'	'
Deposits not covered by insurance	$7,912,547	$6,230,011	'	'	'	'	'	'	'
Concentration risk, percentage	'	'	12.00%	10.00%	13.00%	20.00%	22.00%	20.00%	22.00%
Number of vendors	'	'	1	1	1	1	1	1	1

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 2) (Customer Concentration Risk)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
		Customer		Customer
Total sales	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	'	16.00%	'	14.00%
Concentration risk, benchmark description	'more than 10	'	'more than 10	'
Number of customers	'	1	'	1
Concentration risk, description	'no customer accounted for more than 10% of the Company's total sales	'	'no customer accounted for more than 10% of the Company's total sales	'
Accounts receivable	'	'	'	'
Concentration Risk [Line Items]	'	'	'	'
Concentration risk, percentage	12.00%	15.00%	12.00%	15.00%
Number of customers	1	1	1	1

SUMMARY_OF_SIGNIFICANT_ACCOUNT8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 3) (Noncontrolling Interest, Shanghai Zhongxing)	Sep. 30, 2013
Noncontrolling Interest | Shanghai Zhongxing	'
Noncontrolling Interest [Line Items]	'
Percentage of ownership held	1.00%

TRADE_ACCOUNTS_RECEIVABLE_Summ

TRADE ACCOUNTS RECEIVABLE - Summary of components of trade accounts receivable (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Accounts Receivable, Net [Abstract]	'	'
Accounts receivable	$17,179,460	$18,007,051
Less: allowance for doubtful accounts	-4,487,830	-5,028,243
Trade accounts receivable, net	$12,691,630	$12,978,808

TRADE_ACCOUNTS_RECEIVABLE_Deta

TRADE ACCOUNTS RECEIVABLE (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accounts Receivable, Net [Abstract]	'	'	'	'
Accounts receivable written off	$96,250	$155,296	$347,395	$310,461
Accounts receivable written off against previous allowance for doubtful accounts	'	'	$364,608	$0

OTHER_CURRENT_ASSETS_Summary_o

OTHER CURRENT ASSETS - Summary of components of other current assets (Details) (USD $)	Sep. 30, 2013		Mar. 31, 2013
Other Current Assets [Abstract]	'		'
Prepaid rental expenses	$1,730,847		$647,489
Lease rights transfer fees	72,916	[1]	247,789	[1]
Prepaids and other current assets	337,039		326,221
Total	$2,140,802		$1,221,499
[1]	Lease rights transfer fees are paid by the Company to secure store rentals in coveted areas. These additional costs of acquiring the right to lease new store locations are capitalized and amortized over the period of the initial lease term.

PROPERTY_AND_EQUIPMENT_Summary

PROPERTY AND EQUIPMENT - Summary of components of property and equipment (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Total	$21,316,243	$20,765,612
Less: Accumulated depreciation	-8,715,652	-7,476,960
Construction-in-progress	112,372	'
Property and equipment, net	12,712,963	13,288,652
Building	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	1,144,326	1,119,053
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	14,298,631	13,956,605
Office equipment and furniture	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	5,438,104	5,264,996
Motor vehicles	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	$435,182	$424,958

PROPERTY_AND_EQUIPMENT_Detail_

PROPERTY AND EQUIPMENT (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation expense	$512,065	$645,543	$1,061,755	$1,217,959

ADVANCES_TO_SUPPLIERS_Summary_

ADVANCES TO SUPPLIERS - Summary of components of advance to suppliers (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Advances To Suppliers [Abstract]	'	'
Advance to suppliers	$14,394,521	$19,119,231
Less: allowance for doubtful accounts	-3,323,872	-3,596,197
Advance to suppliers, net	$11,070,649	$15,523,034

ADVANCES_TO_SUPPLIERS_Detail_T

ADVANCES TO SUPPLIERS (Detail Textuals) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Advances To Suppliers [Abstract]	'	'
Advances to suppliers written off against previous allowance for doubtful accounts	$452,246	$0

LONG_TERM_DEPOSITS_Details

LONG TERM DEPOSITS (Details) (USD $)	Sep. 30, 2013		Mar. 31, 2013
Long Term Deposits [Abstract]	'		'
Long term rental deposit	$2,823,014	[1]	$2,760,665	[1]
Long term deposit for land use right	1,361,303	[2]	'	[2]
Total	$4,184,317		$2,760,665
[1]	Money deposited with or advanced to landlords for securing retail store leases for which the Company does not anticipate applying or being returned within the next twelve months. Most of the Company's landlords require a minimum of nine months' rent being paid upfront plus additional deposits.
[2]	Full prepayment for the purchase of land use right to a property planned as a TCM Plant. The Company has received the official land use right certificate on October 10, 2013, although construction has not begun.

OTHER_NONCURRENT_ASSETS_Summar

OTHER NONCURRENT ASSETS - Summary of components of other noncurrent assets (Details) (USD $)	Sep. 30, 2013		Mar. 31, 2013
Other Assets, Noncurrent Disclosure [Abstract]	'		'
Prepayment for lease of land use right - noncurrent	$5,460,500	[1]	$5,419,600	[1]
Lease rights transfer fees-noncurrent	'	[2]	11,726	[2]
Total	$5,460,500		$5,431,326
[1]	Payments made to a local government in connection with entering into a 30-year operating land lease agreement.
[2]	Lease rights transfer fees are paid by the Company to secure store rentals in coveted areas. These additional costs of acquiring the right to lease new store locations are capitalized and amortized over the period of the initial lease term.

OTHER_NONCURRENT_ASSETS_Detail

OTHER NONCURRENT ASSETS (Detail Textuals)	6 Months Ended	12 Months Ended
	Sep. 30, 2013	Mar. 31, 2013
Other Assets, Noncurrent Disclosure [Abstract]	'	'
Term of agreement for operating land lease	'30 years	'30 years

INTANGIBLE_ASSETS_Summary_of_c

INTANGIBLE ASSETS - Summary of components of net intangible assets (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Intangible Assets [Line Items]	'	'
Total other intangible assets	$1,606,350	$1,570,872
Less: accumulated amortization	-456,369	-368,614
Intangible assets, net	1,149,981	1,202,258
Licenses and permits	'	'
Intangible Assets [Line Items]	'	'
Total other intangible assets	1,130,217	1,104,801
Software	'	'
Intangible Assets [Line Items]	'	'
Total other intangible assets	$476,133	$466,071

INTANGIBLE_ASSETS_Detail_Textu

INTANGIBLE ASSETS (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization expense of intangibles	$39,584	$38,766	$78,831	$77,216

SHORTTERM_LOAN_PAYABLE_Detail_

SHORT-TERM LOAN PAYABLE (Detail Textuals)	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	USD ($)	Short term loan	Short term loan
		Industrial And Commercial Bank Of China	Industrial And Commercial Bank Of China
		USD ($)	CNY
Short-term Debt [Line Items]	'	'	'
Short term loan	$163,000	$163,000	1,000,000
Percentage of interest rate on short term loan	'	6.60%	6.60%

TAXES_Summary_of_reconciliatio

TAXES - Summary of reconciliation of U.S. statutory tax rates with effective tax rate (Details)	3 Months Ended				6 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Tax Disclosure [Abstract]	'		'		'		'
U.S. Statutory rates	34.00%		34.00%		34.00%		34.00%
Foreign income not recognized in the U.S.	-34.00%		-34.00%		-34.00%		-34.00%
China income taxes	25.00%		25.00%		25.00%		25.00%
Exemption rendered by local tax authorities	'	[1]	-25.00%	[1]	'	[1]	-25.00%	[1]
Change in valuation allowance	-32.10%	[2]	'	[2]	-31.00%	[2]	'	[2]
Others	0.70%	[3]	0.00%	[3]	0.30%	[3]	0.40%	[3]
Effective tax rate	-7.80%		0.00%		-6.30%		-0.40%
[1]	Qianhong Agriculture enjoyed income tax waiver as an agriculture company since its start in 2010.
[2]	Certain subsidiaries incurred operating loss in the three and six months ended September 30, 2013.
[3]	Represent expenses incurred by the Company that were not deductible for PRC income tax.

TAXES_Summary_of_taxes_payable

TAXES - Summary of taxes payable (Details 1) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Tax Disclosure [Abstract]	'	'
VAT	$314,455	$334,833
Income tax	54,634	7,628
Others	10,892	29,172
Total taxes payable	$379,981	$371,633

TAXES_Detail_Textuals

TAXES (Detail Textuals) (USD $)	3 Months Ended	6 Months Ended
	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Tax Disclosure [Abstract]	'	'	'
Expenses incurred but not deductible for PRC income tax and PRC income tax exemptions	0.00%	'	0.40%
Net operating loss carryforwards	'	$1,409,000	'
Percentage of the valuation allowance recorded	'	100.00%	'
Change in valuation allowance	'	$12,000	$46,000

POSTRETIREMENT_BENEFITS_Detail

POSTRETIREMENT BENEFITS (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Compensation and Retirement Disclosure [Abstract]	'	'	'	'
Employment benefits and pension	$176,883	$81,799	$321,947	$245,945

RELATED_PARTY_TRANSACTIONS_AND2

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS - Amounts payable to related parties (Details) (USD $)	Sep. 30, 2013		Mar. 31, 2013
Related Party Transaction [Line Items]	'		'
Payables - related parties	$2,104,735		$1,224,417
Cofounders	'		'
Related Party Transaction [Line Items]	'		'
Payables - related parties	576,818	[1]	576,818	[1]
Director	'		'
Related Party Transaction [Line Items]	'		'
Payables - related parties	$1,527,917	[2]	$647,599	[2]
[1]	As of September 30, 2013 and March 31, 2013, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements.
[2]	Due to foreign exchange restrictions, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. In addition, Mr. Lei Liu lent about $600,000 to purchase a piece of land use right.

RELATED_PARTY_TRANSACTIONS_AND3

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Related Party Transaction [Line Items]	'	'	'	'	'
Rent expense	$48,702	$46,770	$97,062	$95,028	'
Notes payable	6,547,710	'	6,547,710	'	7,186,453
Mr. Lei Liu	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Amount received from related party debt	'	'	$600,000	'	'

PURCHASE_OPTION_DERIVATIVE_LIA2

PURCHASE OPTION DERIVATIVE LIABILITY - Summary of assumptions to estimate fair value (Details) (Derivative option, USD $)	6 Months Ended
	Sep. 30, 2013		Apr. 28, 2010
Derivative option	'		'
Derivative [Line Items]	'		'
Stock price	$0.70	[1]	'
Exercise price	$6.25	[1]	$6.25
Annual dividend yield	0.00%	[1]	'
Expected term (years)	'1 year 6 months 18 days	[1]	'
Risk-free interest rate	0.33%	[1]	'
Expected volatility	106.98%	[1]	'
[1]	As of September 30, 2013, the option was not exercised.

PURCHASE_OPTION_DERIVATIVE_LIA3

PURCHASE OPTION DERIVATIVE LIABILITY (Detail Textuals) (USD $)	1 Months Ended		3 Months Ended			6 Months Ended
	Apr. 22, 2010	Apr. 28, 2010	Sep. 30, 2013		Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012
Derivative [Line Items]	'	'	'		'	'		'
Gain (loss) on change in fair value option	'	'	($21,049)		$25,905	($8,384)		$25,747
Derivative option	'	'	'		'	'		'
Derivative [Line Items]	'	'	'		'	'		'
Option issued to purchase common stock	'	100	'		'	'		'
Number of option issued to underwriters (in shares)	'	105,000	'		'	105,000		'
Percent shares sold in public offering	'	3.00%	'		'	'		'
Exercise price	'	$6.25	$6.25	[1]	'	$6.25	[1]	'
Percent price of shares sold in public offering	'	125.00%	'		'	'		'
Option as a liability decrease in additional paid-in capital	402,451	'	'		'	'		'
Liability recognize option's fair value	402,451	'	'		'	'		'
Gain (loss) on change in fair value option	'	'	($1,036)		($25,905)	$11,629		($25,747)
Fair valuation techniques	'	'	'		'	'lack-Scholes Option Pricing Model		'
[1]	As of September 30, 2013, the option was not exercised.

WARRANTS_Details

WARRANTS (Details) (Common Stock Warrants, USD $)	6 Months Ended
	Sep. 30, 2013
Common Stock Warrants	'
Class of Warrant or Right [Line Items]	'
Stock price	$0.70	[1]
Exercise price	1.2	[1]
Annual dividend yield	0.00%	[1]
Expected term (years)	'2 years 11 months 27 days	[1]
Risk-free interest rate	0.63%	[1]
Expected volatility	99.19%	[1]
[1]	As of September 30, 2013, the warrants had not been exercised.

WARRANTS_Detail_Textuals

WARRANTS (Detail Textuals) (Common Stock Warrants, USD $)	1 Months Ended	6 Months Ended
	Sep. 26, 2013	Sep. 30, 2013
Class of Warrant or Right [Line Items]	'	'
Stock purchase price per share	'	1.2	[1]
Fair value estimation method	'	'Black-Scholes Model
Increase of prepaid service expense	$33,606	'
Fair value of warrants	33,606	'
Loss from changes in fair value of warrant liability	$20,012	'
Consulting firm	'	'
Class of Warrant or Right [Line Items]	'	'
Common stock purchase warrant	150,000	'
Stock purchase price per share	1.2	'
[1]	As of September 30, 2013, the warrants had not been exercised.

STOCKHOLDERS_EQUITY_Detail_Tex

STOCKHOLDER'S EQUITY (Detail Textuals) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 26, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 26, 2013

Sep. 26, 2013

1-May-13

1-May-13

Nov. 01, 2012

1-May-12

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jan. 16, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Aug. 01, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Consulting firm

Consulting firm

Consulting firm

Restricted Stock

Common Stock

Legal Counsel

Legal Counsel

Legal Counsel

Legal Counsel

Legal Counsel

Group of 46 employees

Group of 46 employees

Group of 46 employees

Group of 46 employees

Group of 46 employees

Group of 46 employees

Group of 46 employees

Group of 46 employees

Group of 46 employees

Mr. Ming Zhao

Mr. Ming Zhao

Mr. Ming Zhao

Mr. Ming Zhao

Mr. Ming Zhao

Consulting firm

Consulting firm

Restricted Stock

Common Stock

Common Stock

Common Stock

Common Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Restricted Stock

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

Stock incentive plan

General and Administrative Expense

General and Administrative Expense

General and Administrative Expense

General and Administrative Expense

Selling Expense

Selling Expense

Selling Expense

Selling Expense

Selling Expense

Installment

Employee

Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of employees in a group

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

46

'

'

'

'

'

'

'

'

'

Common stock issuable as share-based compensation (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

2,340

'

'

'

'

297,000

'

'

'

'

40,000

'

'

'

'

Common stock issuable for services every six month (in shares)

'

'

'

'

'

'

'

350,000

'

2,340

2,340

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional shares issuable for services (in shares)

'

'

'

'

'

'

'

'

'

'

'

2,340

2,340

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

General and administrative expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19,612

$19,612

$39,224

$39,011

'

$7,226

$7,190,000

$15,452

$15,126

'

$0

$0

$8,500

$8,500

Trading value of common stock, per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$0.66

$0.72

$1.07

'

'

'

'

'

'

'

'

'

'

$1.70

'

'

'

'

Service compensation expense

$772

$1,252

$1,563

$2,719

'

$2,445

$2,445

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of equal quarterly installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

Term of service agreement

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Trading value of common stock

'

'

'

'

'

'

'

'

$0.51

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_Detail_Tex1

STOCKHOLDER'S EQUITY (Detail Textuals 1)	6 Months Ended
	Sep. 30, 2013
Stockholders Equity Note [Abstract]	'
Percentage of net income set aside by subsidiaries and VIEs in PRC	10.00%
Threshold limit for total amount set aside in the reserve fund of registered capital by subsidiaries and VIEs in PRC	50.00%

EARNINGS_PER_SHARE_Summary_of_

EARNINGS PER SHARE - Summary of reconciliation of basic and diluted earnings per share computation (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Net loss attributable to controlling interest	($546,062)	($1,528,449)	($1,333,578)	($993,562)
Weighted average shares used in basic computation	13,609,003	13,588,569	13,609,003	13,575,550
Diluted effect of purchase options and warrants	'	'	'	'
Diluted effect of restricted shares	'	'	'	'
Weighted average shares used in diluted computation	13,609,003	13,588,569	13,609,003	13,575,550
Loss per share - Basic:	'	'	'	'
Net loss before noncontrolling interest	($0.04)	($0.11)	($0.10)	($0.07)
Add: Net loss attributable to noncontrolling interest	'	'	'	'
Net loss attributable to controlling interest	($0.04)	($0.11)	($0.10)	($0.07)
Loss per share - Diluted:	'	'	'	'
Net loss before noncontrolling interest	($0.04)	($0.11)	($0.10)	($0.07)
Add: Net loss attributable to noncontrolling interest	'	'	'	'
Net loss attributable to controlling interest	($0.04)	($0.11)	($0.10)	($0.07)

EARNINGS_PER_SHARE_Detail_Text

EARNINGS PER SHARE (Detail Textuals) (Options)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Options	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from calculation of diluted earnings per share	105,000	105,000	150,000	150,000

SEGMENTS_Summarized_informatio

SEGMENTS - Summarized information by segment of continuing operation (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	$16,855,421	$26,665,114	$32,191,940	$59,512,445	'
Cost of goods	13,907,018	23,242,917	25,642,368	50,945,471	'
Gross profit	2,948,403	3,422,197	6,549,572	8,566,974	'
Selling expenses	2,979,131	2,102,621	4,659,973	3,960,845	'
General and administrative expenses	491,981	1,310,313	3,132,799	4,156,892	'
(Loss) income from operations	-522,709	9,263	-1,243,200	449,237	'
Depreciation and amortization	'	'	1,140,586	1,295,175	'
Total assets	70,265,404	'	70,265,404	'	67,838,021
Operating Segments	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	16,855,421	26,665,114	32,191,940	59,512,445	'
Cost of goods	13,907,018	23,242,917	25,642,368	50,945,471	'
Gross profit	2,948,403	3,422,197	6,549,572	8,566,974	'
Selling expenses	2,979,131	2,102,621	4,659,973	3,952,907	'
General and administrative expenses	491,981	1,310,313	3,132,799	4,164,830	'
(Loss) income from operations	-522,709	9,263	-1,243,200	449,237	'
Depreciation and amortization	551,650	684,309	1,140,586	1,295,175	'
Total capital expenditures	1,402,894	270,860	1,520,938	487,314	'
Total assets	70,265,404	88,245,098	70,265,404	88,245,098	'
Operating Segments | Retail drugstores	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	11,052,942	10,497,948	21,965,332	19,452,405	'
Cost of goods	8,544,744	7,690,140	16,672,215	14,319,144	'
Gross profit	2,508,198	2,807,808	5,293,117	5,133,261	'
Selling expenses	1,574,104	2,044,728	3,248,351	3,844,400	'
General and administrative expenses	1,264,804	13,001,790	2,831,847	3,018,426	'
(Loss) income from operations	-330,710	-537,099	-787,081	-1,729,565	'
Depreciation and amortization	410,521	568,012	867,839	1,034,951	'
Total capital expenditures	1,386,806	268,772	1,503,514	484,682	'
Total assets	34,714,300	47,349,821	34,714,300	47,349,821	'
Operating Segments | Drug wholesale	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	5,802,479	16,167,166	10,226,608	37,535,949	'
Cost of goods	5,362,274	15,552,777	8,970,153	36,396,678	'
Gross profit	440,205	614,389	1,256,455	1,139,271	'
Selling expenses	1,405,027	57,893	1,411,622	108,507	'
General and administrative expenses	-818,103	-22,842	195,565	1,104,512	'
(Loss) income from operations	-146,719	579,338	-350,732	-73,748	'
Depreciation and amortization	140,867	116,000	272,225	252,168	'
Total capital expenditures	16,088	2,088	17,424	2,632	'
Total assets	28,703,706	34,269,871	28,703,706	34,269,871	'
Operating Segments | Herb farming	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	'	'	'	2,524,091	'
Cost of goods	'	'	'	229,649	'
Gross profit	'	'	'	2,294,442	'
Selling expenses	'	'	'	'	'
General and administrative expenses	45,280	32,976	105,387	41,892	'
(Loss) income from operations	-45,280	-32,976	-105,387	2,252,550	'
Depreciation and amortization	262	297	522	8,056	'
Total capital expenditures	'	'	'	'	'
Total assets	$6,847,398	$6,625,406	$6,847,398	$6,625,406	'

SEGMENTS_Summary_of_net_revenu

SEGMENTS - Summary of net revenue from external customers (Details 1) (Operating Segments [Member], USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Retail drugstores	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	$11,052,942	$10,497,948	$21,965,332	$19,452,405
Retail drugstores | Prescription drugs	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	4,637,114	4,304,562	9,924,263	8,334,655
Retail drugstores | Over-the-counter drugs	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	4,089,736	3,111,558	8,015,176	5,737,825
Retail drugstores | Nutritional supplements	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	647,177	1,713,605	1,207,014	2,542,891
Retail drugstores | Traditional Chinese medicine	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	907,267	935,439	1,428,513	1,802,140
Retail drugstores | Sundry products	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	473,882	173,814	771,174	396,753
Retail drugstores | Medical devices	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	297,766	258,970	619,192	628,141
Drug wholesale	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	5,802,479	16,167,166	10,226,608	37,535,949
Drug wholesale | Prescription drugs	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	4,276,822	8,404,741	7,649,675	21,125,002
Drug wholesale | Over-the-counter drugs	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	96,125	3,318,318	875,345	7,851,391
Drug wholesale | Nutritional supplements	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	875	4,231,039	261,130	8,339,633
Drug wholesale | Traditional Chinese medicine	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	210,921	927	213,787
Drug wholesale | Sundry products	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	1,428,657	901	1,432,811	1,983
Drug wholesale | Medical devices	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	1,246	6,720	4,153
Chinese herbs Farming	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	'	'	2,524,091
Chinese herbs Farming | Prescription drugs	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	'	'	'
Chinese herbs Farming | Over-the-counter drugs	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	'	'	'
Chinese herbs Farming | Nutritional supplements	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	'	'	'
Chinese herbs Farming | Traditional Chinese medicine	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	'	'	2,524,091
Chinese herbs Farming | Sundry products	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	'	'	'
Chinese herbs Farming | Medical devices	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenue from external customers	'	'	'	'

SEGMENTS_Detail_Textuals

SEGMENTS (Detail Textuals)	6 Months Ended
	Sep. 30, 2013
	Segment
Segment Reporting [Abstract]	'
Number of reportable segments	3

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES - Summary of minimum rental payments under leases (Details) (USD $)	Sep. 30, 2013
Commitments and Contingencies [Line Items]	'
2014	$2,657,105
2015	930,284
2016	548,588
2017	421,391
2018	344,608
Thereafter	339,718
Retail drugstores	'
Commitments and Contingencies [Line Items]	'
2014	2,417,962
2015	658,704
2016	259,673
2017	132,476
2018	55,693
Thereafter	19,203
Drug wholesale	'
Commitments and Contingencies [Line Items]	'
2014	239,143
2015	271,580
2016	288,915
2017	288,915
2018	288,915
Thereafter	320,695
Herb farming	'
Commitments and Contingencies [Line Items]	'
2014	'
2015	'
2016	'
2017	'
2018	'
Thereafter	'

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Total rent expense	$923,572	$1,218,696	$1,889,150	$2,250,441